Open AccessVEGF‐Targeted Therapy in Metastatic Renal Cell Carcinoma
Author(s) -
Rini Brian I.
Publication year - 2005
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.10-3-191
Subject(s) - medicine , renal cell carcinoma , targeted therapy , cancer research , clinical trial , vascular endothelial growth factor , genetic enhancement , blockade , oncology , vegf receptors , cancer , receptor , gene , biology , biochemistry
L earning O bjectives After completing this course, the reader will be able to: Describe the biology underlying clear cell RCC, including inactivation of the von Hippel‐Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression. Describe the mechanisms by which agents currently undergoing clinical testing in metastatic RCC inhibit VEGF. Describe the preliminary clinical results seen with VEGF inhibition in metastatic RCC.Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com